Universität zu Köln

Weller, Johannes ORCID: 0000-0001-5818-5392, Schaefer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael ORCID: 0009-0000-1485-7820, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Guresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich and Schneider, Matthias (2022). Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. J. Neuro-Oncol., 159 (1). S. 95 - 102. NEW YORK: SPRINGER. ISSN 1573-7373

Full text not available from this repository.

Abstract

Purpose The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy. Methods The impact of obesity (BMI >= 30 kg/m(2)) on overall survival (OS) and progression-free survival (PFS) was investigated with Kaplan-Meier analysis and log-rank tests. A multivariable Cox regression analysis was performed including known prognostic factors as covariables. Results Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7-30.8) vs. 43.2 (32.5-54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8-18.9) vs 17.6 (14.7-20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53-4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm. Conclusion Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Weller, Johannes UNSPECIFIED orcid.org/0000-0001-5818-5392 UNSPECIFIED Schaefer, Niklas UNSPECIFIED UNSPECIFIED UNSPECIFIED Schaub, Christina UNSPECIFIED UNSPECIFIED UNSPECIFIED Potthoff, Anna-Laura UNSPECIFIED UNSPECIFIED UNSPECIFIED Steinbach, Joachim P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlegel, Uwe UNSPECIFIED UNSPECIFIED UNSPECIFIED Sabel, Michael UNSPECIFIED orcid.org/0009-0000-1485-7820 UNSPECIFIED Hau, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Seidel, Clemens UNSPECIFIED UNSPECIFIED UNSPECIFIED Krex, Dietmar UNSPECIFIED UNSPECIFIED UNSPECIFIED Goldbrunner, Roland UNSPECIFIED UNSPECIFIED UNSPECIFIED Pietsch, Torsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Tzaridis, Theophilos UNSPECIFIED UNSPECIFIED UNSPECIFIED Zeyen, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Borger, Valeri UNSPECIFIED UNSPECIFIED UNSPECIFIED Guresir, Erdem UNSPECIFIED UNSPECIFIED UNSPECIFIED Vatter, Hartmut UNSPECIFIED UNSPECIFIED UNSPECIFIED Herrlinger, Ulrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Schneider, Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-689201
DOI:	10.1007/s11060-022-04046-z
Journal or Publication Title:	J. Neuro-Oncol.
Volume:	159
Number:	1
Page Range:	S. 95 - 102
Date:	2022
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1573-7373
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language BODY-MASS INDEX; SURVIVAL; TEMOZOLOMIDE; ASSOCIATION; PARADOX; HYPERGLYCEMIA; MORTALITY; BENEFIT; DAMAGE Multiple languages Oncology; Clinical Neurology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68920